Allergan’s Botox For Removing Glabellar Lines Yet To Receive SFDA Approval
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline China Investment introduced Allergan-developed Botox into China in October 2006 as a drug for one-sided facial muscle spasms and eyelid twitching. However, the popular wrinkle-removing Botox injection has yet to receive China's State FDA approval for treatment of glabellar lines between eyebrows. GSK officials say Botox for removing glabellar lines is still in clinical trials, but declined to comment on the progress or expected market prospects for the drug in China. On the other hand, botulinum toxin type A produced by local firm Lanzhou Institute of Biological Products has captured the China market. Although it has not been approved for glabellar lines removal, the drug has gained widespread cosmetic use in many domestic plastics institutions. (Click here for more - Chinese Language)
You may also be interested in...
China SFDA Moves Botulinum Toxin Type A Under Toxic Drug Category
SHANGHAI - China's Ministry of Health and State FDA have moved neurotoxin Botox (botulinum toxin type A) under toxic drug control, the two institutions declared in a joint notice July 22
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.